Rhythm Pharmaceuticals Inc. (Nasdaq: RYTM) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, Nov. 13, 2017 (GLOBE NEWSWIRE) --

What:
Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Keith M. Gottesdiener, MD, Chief Executive Officer, will ring the Closing Bell.

Where:
Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When:
Tuesday, November 14, 2017 – 3:45 p.m. to 4:00 p.m. ET

Rhythm Pharmaceuticals, Inc. Contact:
Media contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

Investor contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannahd@sternir.com

Nasdaq MarketSite Media Contact:
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://ift.tt/1ejh9f4.

For photos from ceremonies and events, please visit our Instagram page:
http://ift.tt/1kkvASh

For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:
http://ift.tt/T4ODTg

Webcast:
A live stream of the Nasdaq Closing Bell will be available at:
http://ift.tt/NYKeUb or http://ift.tt/1gnW0EA

Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://ift.tt/2doY7Jl and click on the market close of your choice.

About Rhythm Pharmaceuticals, Inc.
Rhythm is a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. Rhythm supports The Genetic Obesity Project (http://ift.tt/2a9pW6r), which is dedicated to improving the understanding of severe obesity that is caused by specific genetic defects. The company is based in Boston, MA.

About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://ift.tt/1ySbdC8

-NDAQA-

Let's block ads!(Why?)

Read Again Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) to Ring The Nasdaq Stock Market Closing Bell : http://ift.tt/2zFhBVz

Let's block ads! (Why?)